JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

The diagnostic role of A-kinase anchoring protein 12, Bcl-2 and high mobility group box Protein-1 levels in breast cancer
Received Date : 27 Jun 2019
Accepted Date : 20 Sep 2019
Available Online : 25 Sep 2019
Doi: 10.1016/j.jons.2019.09.003 - Article's Language: EN
J Oncol Sci 5 (2019) 90-95
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Aim: Despite the improved diagnosis and treatment methods in recent years, the number of new breast cancer cases does not reduce and the mortality rates are still so high. There are several proteins that play significant roles in carcinogenesis process and hold a great potential to be used as a marker of cancer diagnosis. A-Kinase Anchoring Protein 12 (AKAP12) regulates gene expression in cell cycle and apoptosis while B- cell Lymphoma 2 (BCL2) family proteins and inhibitors of apoptosis proteins are the major regulators of the apoptotic process. High mobility group box 1 (HMGB1) has multiple pro-tumor roles in tumor development. In our study, we aimed to determine the usability and sensitivity of AKAP12, BCL2 and HMGB1 proteins as a marker of breast cancer diagnosis, and further investigate the relationship among these proteins. Material and Methods: Between 2014 and 2017, a total number of 82 participants, 60 of them were diagnosed with early stage breast cancer and 22 healthy age-matched people as control group, were included in the study. Serum samples obtained from the groups were investigated in terms of AKAP12, BCL2 and HMGB1 levels by using Enzyme Linked Immuno-Sorbent Assay (ELISA) method. Results: Comparing the patient group with control groups, AKAP12, BCL2 and HMGB1 levels were found to be significantly higher in the patient group (p ¼ 0.009), (p < 0.001) and (p < 0.001), respectively. Conclusion: The findings of our results indicate that these proteins levels may be used as markers in the diagnosis and follow-up of breast cancer.
KAYNAKLAR
  1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2018;68:394e424. https://doi.org/10.3322/ caac.21492. [Crossref]  [PubMed] 
  2. Gordon T, Grove B, Loftus JC, et al. Molecular cloning and preliminary characterization of a novel cytoplasmic antigen recognized by myasthenia gravis sera. J Clin Investig. 1992;90:992e999. [Crossref]  [PubMed]  [PMC] 
  3. Yoon DK, Jeong CH, Jun HO, et al. AKAP12 induces apoptotic cell death in human fibrosarcoma cells by regulating CDKI-cyclin D1 and caspase-3 activity. Cancer Lett. 2007;254:111e118. [Crossref]  [PubMed] 
  4. Wilhelm T, Lipka DB, Witte T, et al. Epigenetic silencing of AKAP12 in juvenile myelomonocytic leukemia. Epigenetics. 2016:1e10. [Crossref]  [PubMed]  [PMC] 
  5. Boultwood J, Pellagatti A, Watkins F, et al. Low expression of the putative tumour suppressor gene Gravin in chronic myeloid leukaemia, myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2004;126:508e511. [Crossref]  [PubMed] 
  6. Choi MC, Jong HS, Kim TY, et al. AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity. Oncogene. 2004;23:7095e7103. [Crossref]  [PubMed] 
  7. Yıldırım M. Akut L€osemilerde Gravin Ekspresyonunun Prognostik €Onemi. Çukurova Üniversitesi Tıp Fakültesi _Iç Hastalıkları ABD, Uzmanlık Tezi. 2006. Adana (Prof. Dr. Semra PAYDAS¸ ).
  8. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9:47e59. [Crossref]  [PubMed] 
  9. Reed JC, Doctor KS, Godzik A. The domains of apoptosis: a genomics perspective. Sci Signal. 2004;239:re9. [Crossref]  [PubMed] 
  10. Yıldırım M. Mide Kanserinde P52 Ve BCL2 Ekspresyonunun Prognostik €Onemi. Saglık Bakanlıgı Antalya Egitim Ve Aras¸ tırma Hastanesi Tıbbi Onkoloji Klinigi, Yan Dal Uzmanlık Tezi. Antalya: Doç. Dr. Mustafa YILDIZ; 2012.
  11. Minn AJ, Rudin CM, Boise LH, et al. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood. 1995;86:1903e1910. [Crossref]  [PubMed] 
  12. Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood. 2008;111:3322e3330. [Crossref]  [PubMed]  [PMC] 
  13. Yoshino T, Shiina H, Urakami S, et al. Bcl-2 expression as a predictive marker of hormone refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006;12:6116e6124. [Crossref]  [PubMed] 
  14. Dawson SJ, Makretsov N, Blows FM, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Canc. 2010;103:668e675. [Crossref]  [PubMed]  [PMC] 
  15. Kim HS, Moon HG, Han W, et al. COX2 overexpression is a prognostic marker for stage III breast cancer. Breast Canc Res Treat. 2012;132:51e59. [Crossref]  [PubMed] 
  16. Yıldırım M, Süren D, Demirpençe €O, et al. High mobility group box 1 ve Kanser. Acıbadem Üniversitesi Saglık Bilimleri Dergisi. 2014;5:182e186.
  17. Goodwin GH, Sanders C, Johns EW. A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem. 1973;38:14e19. [Crossref]  [PubMed] 
  18. Thomas JO, Stott K. H1 and HMGB1: modulators of chromatin structure. Biochem Soc Trans. 2012;40:341e346. [Crossref]  [PubMed] 
  19. Bustin M. Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol. 1999;19: 5237e5246. [Crossref]  [PubMed]  [PMC] 
  20. Stros M, Muselikova-Polanska E, Pospisilova S, et al. High-affinity binding of tumor-suppressor protein p53 and HMGB1 to hemicatenated DNA loops. Biochemistry. 2004;43:7215e7225. [Crossref]  [PubMed] 
  21. Tang D, Kang R, Zeh HJ, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta Gene Regul Mech. 2010;1799:131e140. [Crossref]  [PubMed]  [PMC] 
  22. Kang R, Zhang Q, Zeh HJ, et al. HMGB1 in cancer: good, bad, or both? Clin Cancer Res. 2013;19:4046e4057. [Crossref]  [PubMed]  [PMC] 
  23. Sun S, Zhang W, Cui Z, et al. High mobility group box-1 and its clinical value in breast cancer. OncoTargets Ther. 2015;8:413e419. [Crossref]  [PubMed]  [PMC] 
  24. Zhang J, Zhang R, Lu WW, et al. Clinical significance of hmgb1 expression in human gastric cancer. Int J Immunopathol Pharmacol. 2014;27:543e551. [Crossref]  [PubMed] 
  25. Zhang L, Han J, Wu H, et al. The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a metaanalysis and literature review. PLoS One. 2014;9:1e8. [Crossref]  [PubMed]  [PMC] 
  26. Feng A, Tu Z, Yin B. The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer. Oncotarget. 2016;7: 20507e20519. [Crossref] 
  27. Hayran M, Hayran M. Saglık Aras¸ tırmaları Için Temel _Istatistik. Ankara: Hayran Yayınevi; 2011.
  28. Xia W, Unger P, Miller L, et al. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res. 2001;61: 5644e5651.
  29. Liu W, Guan M, Su B, et al. Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: correlation with Duke's stage. Cancer Biol Ther. 2010;9:862e871. [Crossref]  [PubMed] 
  30. Gelman IH. Emerging roles for SSeCKS/Gravin/AKAP12 in the control of cell proliferation, cancer malignancy, and barriergenesis. Genes Cancer. 2010;1: 1147e1156. [Crossref]  [PubMed]  [PMC] 
  31. Lin X, Nelson PJ, Frankfort B, et al. Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in cells transformed by src and ras. Mol Cell Biol. 1995;15:2754e2762. [Crossref]  [PubMed]  [PMC] 
  32. Akakura S, Huang C, Nelson PJ, et al. Loss of the SSeCKS/Gravin/AKAP12 gene results in prostatic hyperplasia. Cancer Res. 2008;68:5096e5103. [Crossref]  [PubMed]  [PMC] 
  33. Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005;41:858e887. [Crossref]  [PubMed] 
  34. Su B, Zheng Q, Vaughan MM, et al. SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. Cancer Res. 2006;66:5599e5607. [Crossref]  [PubMed] 
  35. Zhu Y, Hollmen J, Raty R, et al. Investigatory and analytical approaches to differential gene expression profiling in mantle cell lymphoma. Br J Haematol. 2002;119:905e915. [Crossref]  [PubMed] 
  36. Tsujimoto K, Ono T, Sato M, et al. Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J Biol Chem. 2005;280:27638e27644. [Crossref]  [PubMed] 
  37. Carinci F, Piattelli A, Martinelli M, et al. Genetic profiling of central giant cell granuloma of the jaws. J Craniofac Surg. 2005;16:399e407. [Crossref]  [PubMed] 
  38. Jiang BH, Agani F, Passaniti A, et al. V-SRC induces expression of hypoxiainducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997;57:5328e5335.
  39. Soh RYZ, Lim JP, Samy RP, et al. A-kinase anchor protein 12 (AKAP12) inhibits cell migration in breast cancer. Exp Mol Pathol. 2018;105:364e370. [Crossref]  [PubMed] 
  40. Zhang GM, Goyal H, Song LL. Bioinformatics analysis of differentially expressed miRNA-related mRNAs and their prognostic value in breast carcinoma. Oncol Rep. 2018;39:2865e2872. [Crossref] 
  41. Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod. 1998;4:1099e1109. [Crossref]  [PubMed] 
  42. Bouchalova K, Kharaishvili G, Bouchal J, et al. Triple negative breast cancer: BCL2 in prognosis and prediction. Review. Curr Drug Targets. 2014;15: 1166e1175. [Crossref]  [PubMed] 
  43. Brunelle JK, Letai A. Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci. 2009;122:437e441. [Crossref]  [PubMed]  [PMC] 
  44. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994;86:499e504. [Crossref]  [PubMed] 
  45. Lipponen P, Pietilainen T, Kosma VM, et al. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol. 1995;177:49e55. [Crossref]  [PubMed] 
  46. Pietenpol JA, Papadopoulos N, Markowitz S, et al. Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res. 1994;54:3714e3717.
  47. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 1996;15:6979e6990. [Crossref]  [PubMed]  [PMC] 
  48. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22:8590e8607. [Crossref]  [PubMed] 
  49. Leung LK, Wang TT. Paradoxical regulation of Bcl-2 family proteins by 17betaoestradiol in human breast cancer cells MCF-7. Br J Canc. 1999;81:387e392. [Crossref]  [PubMed]  [PMC] 
  50. Wang TT, Phang JM. Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res. 1995;55:2487e2489.
  51. Eom YH, Kim HS, Lee A, et al. BCL2 as a subtype-specific prognostic marker for breast cancer. J Breast Cancer. 2016;19:252e260. [Crossref]  [PubMed]  [PMC] 
  52. Samy N, Ragab HM, El Maksoud NA, et al. Prognostic significance of serum Her2/neu, BCL2, CA 15-3 and CEA in breast cancer patients: a short follow-up. Cancer Biomark. 2010;6:63e72. [Crossref]  [PubMed] 
  53. V€olp K, Brezniceanu ML, B€osser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut. 2006;55:234e242. [Crossref]  [PubMed]  [PMC] 
  54. Pardo M, García A, Thomas B, et al. The characterization of the invasion phenotype of uveal melanoma tumour cells shows the presence of MUC18 and HMG-1 metastasis markers and leads to the identification of DJ-1 as a potential serum biomarker. Int J Cancer. 2006;119:1014e1022. [Crossref]  [PubMed] 
  55. Ishiguro H, Nakaigawa N, Miyoshi Y, et al. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are over expressed and associated with prostate cancer development. The Prostate. 2005;64:92e100. [Crossref]  [PubMed] 
  56. Choi YR, Kim H, Kang HJ, et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res. 2003;63: 2188e2193.
  57. Hirata K, Takada M, Suzuki Y, et al. Expression of receptor for advanced glycation end products (RAGE) in human biliary cancer cells. Hepato- Gastroenterology. 2003;50:1205e1207.
  58. Evans A, Lennard TW, Davies BR. High-mobility group protein 1(Y): metastasisassociated or metastasis-inducing? J Surg Oncol. 2004;88:86e99. [Crossref]  [PubMed] 
  59. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (receptor for advanced glycation endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009;7:17. [Crossref]  [PubMed] 
  60. Kostova N, Zlateva S, Ugrinova I, et al. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Mol Cell Biochem. 2010;337: 251e258. [Crossref]  [PubMed] 
  61. Yang GL, Zhang LH, Bo JJ, et al. Increased expression of HMGB1 is associated with poor prognosis in human bladder cancer. J Surg Oncol. 2012;106:57e61. [Crossref]  [PubMed] 
  62. Kang R, Chen R, Zhang Q, et al. HMGB1 in health and disease. Mol Asp Med. 2014;40C:1e116.
  63. Jiao Y, Wang HC, Fan SJ. Growth suppression and radiosensitivity increase by HMGB1 in breast cancer. Acta Pharmacol Sin. 2007;28:1957e1967. [Crossref]  [PubMed] 
  64. Chalmers SA, Eidelman AS, Ewer JC, et al. A role for HMGB1, HSP60 and Myd88 in growth of murine mammary carcinoma in vitro. Cell Immunol. 2013;282: 136e145. [Crossref]  [PubMed]  [PMC] 
  65. Sun S, Zhang W, Cui Z, et al. High mobility group box-1 and its clinical value in breast cancer. OncoTargets Ther. 2015;8:413e419. [Crossref]  [PubMed]  [PMC]